Results

Total Results: 1,225 records

Showing results for "description".

441. Disposition of Comments for CER 178 Newer Medications for Lower Urinary Tract Symptoms (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/prostatic-hyperplasia-medications_disposition-comments.pdf
     May 26, 2016 - Very clear description of the different SoE definitions.

442. Disposition of Comments Report for Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-ovarian-contraceptives_disposition-comments.pdf
     June 07, 2013 - 4 Commentator & Affiliation Section Comment Response TEP Member 4 Executive Summary The description … Please reword to provide a more detailed description We have revised the sentence to be more precise … The reviewer is correct, and we have revised this description to clarify that probabilistic analysis … This level of understanding and description should be demanded even in an Abstract since this may be

443. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_executive.pdf
     September 01, 2009 - Layout 1 Background Breast cancer is the most frequently diagnosed noncutaneous cancer and the second leading cause of cancer death after lung cancer among women in the United States. In 2008, an estimated 182,460 cases of invasive breast cancer and 67,770 cases of in situ breast cancer were diagnosed, and 40,480 wo…

444. AHRQ Evidence-based Practice Center Program Research Gaps Summary: Telehealth (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ehc-research-gaps-telehealth.pdf
     April 01, 2023 - AHRQ Evidence-based Practice Center Program Research Gaps Summary: Telehealth AHRQ EVIDENCE-BASED PRACTICE CENTER (EPC) PROGRAM RESEARCH GAPS SUMMARY: TELEHEALTH An AHRQ EPC Program publication summarizing evidence gaps identified across recent EPC Program reviews for select healthcare topics addressing telehea…

445. Prevention, Diagnosis, and Management of Opioids, Opioid Misuse and Opioid Use Disorder in Older Adults: Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/opioids-oa-protocol.pdf
     June 29, 2019 - intervention type (e.g., screening tool, model of care, quality improvement initiative) and brief description

446. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ptsd-5-protocol-update-2023.pdf
     January 01, 2023 - Treatment Description 4.

447. PowerPoint Presentation (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-strength-evidence.ppt
     June 01, 2012 - If an intermediate accuracy outcome is used, there should be a description of how the test is related

448. PowerPoint Presentation (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-strength-evidence.ppt
     June 01, 2012 - If an intermediate accuracy outcome is used, there should be a description of how the test is related

449. Research White Paper Biorepositories Addendum Registries For Evaluating Patient Outcomes Third Edition (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/biorepositories-registries-guide-3rd-ed-addendum-white-paper.pdf
     February 01, 2018 - The consent process should involve a description of the physical risks associated with collecting the … secondary research use of identifiable private information and identifiable specimens46: • A general description … research that may be conducted with identifiable private information or identifiable biospecimens; • A description … institutions or investigators that might conduct research with such information and biospecimens; • A description … the identifiable private information or identifiable biospecimens may be stored or maintained, and a description

450. Topic-Brief2-Opioid-Withdrawal (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/topic-brief2-opioid-withdrawal.pdf
     April 01, 2021 - Studies of treatments to support opioid tapering in patients with chronic pain Strategy Description … 200)† Mean 21% (range 6-55%); 5 studies Good: 3 studies Poor: 3 studies 8 Strategy Description … See Appendix B for detailed description of the criteria.

451. Topic-Brief2-Opioid-Withdrawal (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/topic-brief2-opioid-withdrawal.pdf
     April 01, 2021 - Studies of treatments to support opioid tapering in patients with chronic pain Strategy Description … 200)† Mean 21% (range 6-55%); 5 studies Good: 3 studies Poor: 3 studies 8 Strategy Description … See Appendix B for detailed description of the criteria.

452. Disposition of Comments_Comparative Effectiveness Review No. 262_Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings: Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-262-pharmacotherapy-alcohol-disposition-comments.pdf
     November 07, 2023 - Page 47: A brief description of the arms and results of the COMBINE trial (such as that presented on … We have added a description of COMBINE to Section 3.1.3, acamprosate versus naltrexone. … - Otherwise, tables and description are adequate and descriptive Thank you.

453. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/crohns-disease_research-protocol.pdf
     September 01, 2010 - Background and Objectives for the Systematic Review Background Description of disease. … Burrill Crohn’s initial description of this disease suggested that it could be cured with wide surgical … These studies adhered to the commonly held concepts of high quality, including the following: a clear description

454. Disposition of Comments CER 194 Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-194-disposition-comments-inhaled-corticosteroids.pdf
     March 19, 2018 - Further description as to the domains that led to downgrading a given outcome are provided in the … Further description as to the domains that led to downgrading a given outcome within each intervention … Further description as to the domains that led to downgrading a given outcome within each intervention … Public reviewer #1, Anonymous KQ1c A description of how dosing (frequency and cumulative dose) differs

455. Disposition of Comments for Treatments for Seasonal Allergic Rhinitis (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/allergy-seasonal_disposition-comments.pdf
     July 17, 2013 - This has been corrected in the “Description of Included Studies” for this comparison, in Table 10 (Drugs … and Usability It might be beneficial if the Authors reviewed the document for consistency of the description … In the Results section, funding is reported in the narrative description of the evidence for each comparison … Description of PICOTS was nicely done and a new term for me, one who spends the day seeing patients.

456. Treatments for Adults with Schizophrenia: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/schizophrenia-adult_research-protocol.pdf
     September 23, 2016 - Definition and description of schizophrenia in the DSM-5.

457. Strategies to De-escalate Aggressive Behavior in Psychiatric Patients (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/aggression_disposition-comments.pdf
     July 14, 2016 - discussion of the study by Putkonen and colleagues (2013), the text describes on p. 66 gives an excellent description

458. Disposition of Comments_Technical Brief No. 45: Long COVID Models of Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/long-covid-disposition-comments.pdf
     January 01, 2022 - The Background section is intended to provide contextual information on long COVID to inform our description … Introduction Description of manifestations should include a more complete array that also includes: … The description of research definitions seems out of place and distracts from flow. … Comment: Seems inaccurate in the description of symptoms "persisting." … We judged that this was distinct enough to warrant a separate model description, and is consistent

459. Public-Reporting-Cost-Measures Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/public-reporting-cost-measures_research-protocol.pdf
     January 13, 2014 - Amendments In the event of protocol amendments, the date of each amendment will be accompanied by a description

460. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/nppv-respiratory-failure_research-protocol.pdf
     April 21, 2011 - Amendments In the event of protocol amendments, the date of each amendment will be accompanied by a description